Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium.
Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium.
复制标题
与良性前列腺上皮相比，人类前列腺癌中 1 型胰岛素样生长因子 (IGF) 受体的蛋白质和信使核糖核酸 (mRNA) 减少，IGF-II mRNA 增加。
DOI：
--
复制
发表时间：
1996
影响因子：
5.8
通讯作者：
S. Plymate
中科院分区：
文献类型：
--
作者：
M. Tennant;J. Thrasher;P. A. Twomey;R. Drivdahl;R. Birnbaum;S. Plymate
胰岛素样生长因子（IGFs）和1型IGF受体（IGF-R）参与人前列腺的正常生长和发育。IGF-R和IGFs水平的变化已被证明是几种恶性肿瘤。采用免疫组化和原位杂交方法比较IGF-R和IGF-II在前列腺良性上皮、高级别前列腺上皮内瘤（PIN）和腺癌组织中的表达。信使核糖核酸（mRNA）杂交信号和IGF-R的免疫反应主要定位于上皮细胞，间质中的信号较少。与良性上皮相比，PIN和癌细胞中IGF-R mRNA分别降低42%和35%（P < 0.0001）。与良性上皮相比，PIN和恶性上皮中IGF-R的表达分别降低了32%和42%（P < 0.004）。IGF-II mRNA也主要定位于上皮细胞。IGF-II mRNA在腺癌组织中的表达较良性上皮组织高30%（P < 0.03）。IGF-II的免疫反应性定位于基质和上皮。与良性上皮相比，癌细胞中IGF-II的蛋白水平没有显著增加。1型IGF受体的减少和IGF-II mRNA的增加可能影响前列腺癌的增殖和分化。
Insulin-like growth factors (IGFs) and the type 1 IGF receptor (IGF-R) are involved in normal growth and development of the human prostate. Changes in levels of IGF-R and IGFs have been shown for several malignancies. Immunohistochemistry and in situ hybridization were performed to compare the expression of IGF-R and IGF-II in vivo in prostate tissue containing benign epithelium, high grade prostate intraepithelial neoplasia (PIN), and adenocarcinoma. Messenger ribonucleic acid (mRNA) hybridization signals and immunoreactivity for IGF-R were localized primarily to epithelial cells, with less signal in stroma. IGF-R mRNA was significantly decreased by 42% in PIN and 35% in cancer cells compared to that in benign epithelium (P < 0.0001). IGF-R immunostaining was significantly decreased by 32% in PIN and by 42% in malignant epithelium compared to that in benign epithelium (P < 0.004). IGF-II mRNA was also localized primarily to epithelial cells. IGF-II mRNA was significantly increased by 30% in adenocarcinoma compared to that in benign epithelium (P < 0.03). Immunoreactivity for IGF-II was localized to both stroma and epithelium. Protein levels for IGF-II were not significantly increased in cancer cells compared to those in benign epithelium. The decrease in the type 1 IGF receptor and increase in IGF-II mRNA may affect prostate cancer proliferation and differentiation.